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Administration of intravenous nitroglycerin in a patient 
with idiopathic pulmonary hypertension resulted in an 
increase in pulmonary artery pressure associated with 
a decrease in blood How that is best explained by an 
Interest in the use of systemic vasodilators in pulmonary 
hypertension has been spurred by a number of reports dem-
onstrating significant beneficial hemodynamic effects (1-7). 
Although these agents have been effective in some patients, 
success has been limited, and reports of adverse effects 
including death have appeared (8-12). A major limiting 
factor has been the reduction of systemic vascular resistance 
and the resultant systemic arterial hypotension. In addition, 
a decrease in pulmonary vascular resistance may be accom-
panied by an increase in pulmonary blood flow that prevents 
a decrease in pulmonary artery pressure. Nitroglycerin, a 
preferential venodilator, has recently been shown to be highly 
effective in patients with pulmonary hypertension (13). We 
describe here a previously unreported adverse hemodynamic 
effect of intravenous nitroglycerin in a patient with idio-
pathic pulmonary hypertension. 
Case Report 
Clinical features. A 15 year old Hispanic girl with idio-
pathic pulmonary hypertension was admitted to University 
of California-San Diego Medical Center in February 1984 
for cardiac catheterization. She was well until 1980 when 
she developed hoarseness, exertional fatigue and dyspnea. 
Technetium lung scan showed no evidence of emboli and 
disclosed the characteristic fint> mottled appearance of pul-
monary hypertension. In 1 OSl, cardiac catheterization (Ta-
ble 1) revealed moderate pulmonary hypertension, no shunts 
and nonnal cardiac output. Phentolamine and tolazoline in-
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increase in pulmonary vascular resistance. This obser-
vation highlights the need for hemodynamic monitoring 
when potent vasodilators are used in this disorder. 
(J Am Coil CardioI1985;6:490-2) 
fusion reduced both pulmonary and systemic vascular re-
sistances, but pulmonary artery pressure did not decrease. 
Treatment with hydralazine, 50 mg every 6 hours, resulted 
in no significant change in symptoms over a 1 year period 
of follow-up. In 1982, a second cardiac catheterization (Ta-
ble 1) revealed worsening of pUlmonary hypertension. In-
fusions of phentolamine and verapamil did not decrease 
pulmonary vascular resistance. Accordingly, hydralazine was 
discontinued and the patient was discharged without drug 
treatment. Further deterioration prompted a third catheter-
ization. The blood pressure was 110no mm Hg, the pulse 
74 beats/min and the venous pressure 8 cm H20. A left 
parasternal impulse was noted. The second heart sound was 
split narrowly with an increased pulmonary component. A 
grade 2/6 systolic ejection munnur that did not change with 
respiration was heard at the left sternal border. 
Cardiac catheterization and effect of nitroglycerin. 
The current cardiac catheterization study revealed that the 
patient's pulmonary hypertension had not increased since 
1982 (Table 1). The cardiac output measured by thenno-
dilution was consistent with the measured arteriovenous ox-
ygen difference. As expected, the pulmonary vascular re-
sistance was greatly elevated. The systemic vascular resistance 
was slightly elevated, and the ratio between the two resis-
tances was 0.82. One minute after administration of 200 
f,Lg of nitroglycerin by Swan-Ganz catheter, pulmonary ar-
tery pressure increased and aortic pressure decreased (Fig. 
1). The cardiac output measured by thennodilution de-
creased 23% from 4.2 to 3.2 liters/min and the arteriovenous 
oxygen difference widened from 5.0 to 5.4 vol %, a 7% 
reduction of cardiac output assuming a constant oxygen 
consumption. These changes were accompanied by an in-
crease in pulmonary vascular, total pulmonary and systemic 
vascular resistances calculated from standard fonnulas. Ten 
minutes after nitroglycerin infusion, intravascular pressures 
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Table 1. Results of Sequential Cardiac Catheterization Studies 
PAP (mm Hg) 
PAP mean (mm Hg) 
PAWP mean (mm Hg) 
RAP mean (mm Hg) 
ArtP (mm Hg) 
ArtP mean (mm Hg) 
CO (liters/min) 
HR (beats/min) 
Art O2 saturation (%) 
PA O2 saturation (%) 
av02 diff (vol %) 
PVR (dynes's'cm ') 
TPR (dynes·s'cm ') 
SVR (dynes's'cm ') 
Rp/Rs 
6/26/S1 
(no medication) 
70/35 
50 
5 
100/62 
78 
4.54 
4.R 
793 
SRI 
1.339 
0.59 
1J4/S2 
(hydralazine. 
50 mg 
every 6 hours) Control 
103/49 100/50 
69 70 
6 9 
4 
120/65 100165 
S5 7R 
4.36 4.22 
75 
96.7 
66.5 
4.7 5.0 
1,156 1.156 
1.266 1.327 
1,486 1.402 
0.78 0.82 
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2/8/S4 
I Minute 
After 
NTG 
115/65 
80 
4 
S5/60 
74 
3.26 
93 
'!6 
64.6 
5.4 
1.742 
1,963 
1.717 
1.01 
10 Minutes 
After NTG 
110/55 
75 
5 
110/68 
80 
3.51 
76 
1,504 
1,709 
1.709 
0.88 
Art = arterial; ArtP = arterial pressure; av02 diff = arteriovenous oxygen difference; CO = cardiac 
output; HR = heart rate; O2 = oxygen; PA = pulmonary artery; PAP = pulmonary artery pressure; PA WP 
= pulmonary artery wedge pressure; PVR = pulmonary vascular resistance; RAP = right atrial pressure; 
Rp/Rs = pulmonary to systemic vascular resistance ratio; SVR = systemic vascular resistance; TPR = total 
pulmonary resistance. 
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and cardiac output had returned toward normal, Additional 
trials with vasodilators were not attempted, and the patient 
was discharged without medication. 
Discussion 
nitroglycerin cause a decrease in systemic vascular resis-
tance and right atrial pressure. However, we observed an 
increase in systemic vascular resistance and no change in 
right atrial pressure, A decrease in inotropic state might 
explain several of our findings; however, nitroglycerin has 
Prolonged pUlmonary arteriolar vasoconstriction of un-
known origin is thought to be an element in the pathogenesis 
of idiopathic pUlmonary hypertension (14), suggesting that 
vasodilator therapy should be beneficial in this disorder. 
Success with several agents supports this reasoning (1-7), 
but optimism has been tempered by limited clinical efficacy, 
adverse hemodynamic consequences and death (8-12). Al-
though an increase in pulmonary artery pressure has been 
noted after the use of hydralazine, it has been associated 
with a reduction of pUlmonary vascular resistance and in-
creased pulmonary blood flow (9). Our observations are 
heretofore undescribed and are not readily explicable, Lab-
oratory error could not be reasonably incriminated because 
changes in arteriovenous oxygen difference confirmed the 
direction of the changes in cardiac output. Pulmonary artery 
wedge pressure could only be obtained at baseline for tech-
nical reasons, However, changes in total pulmonary resis-
tance were similar to those of pulmonary vascular resistance. 
Therefore, the potential error introduced by assuming a con-
stant pulmonary artery wedge pressure does not account for 
our observations, 
Possible mechanisms. The mechanisms responsible for 
these changes are not clear, The vasodilating effects of 
Figure 1. Electrocardiogram and aortic (Ao) and pulmonary artery 
(PA) pressures at baseline and 1 minute after nitroglycerin (POST 
NTG) administration recorded on the same gain (each horizontal 
line equals 10 mm Hg) and at the same paper speed (25 mm/s). 
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never been demonstrated to have myocardial depressant 
properties. Pulmonary artery pressure may be increased by 
reflex sympathetic vasoconstriction. The increase in heart 
rate we observed after nitroglycerin administration is con-
sistent with enhanced sympathetic tone. However, although 
sympathetic nerve stimulation can increase pulmonary vas-
cular resistance (15), there is evidence that a vasodilating 
response due to betaz-receptor stimulation may predominate 
when pulmonary vascular tone is increased (16). 
Nitroglycerin may increase venous admixture and the 
pulmonary dead space to tidal volume ratio (17), thereby 
lowering arterial partial pressure of oxygen (Po2); but pul-
monary vasoconstriction in response to hypoxia induced by 
this mechanism is unlikely in view of the minimal changes 
that occurred in arterial Po2 • A primary increase in pul-
monary vascular resistance leading to an increase in pul-
monary artery pressure, a decrease in cardiac output and a 
secondary increase in systemic vascular resistance may ex-
plain our patient's unusual response to nitroglycerin. 
Implications. Although the mechanisms of the para-
doxical increase in pulmonary vascular resistance in re-
sponse to nitroglycerin remain speculative, it is important 
to draw attention to this potentially lethal complication, and 
to reemphasize the need for careful hemodynamic moni-
toring when administering potent vasodilator drugs to pa-
tients with idiopathic pulmonary hypertension. 
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